Related Experiment Video
Updated: Sep 13, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Targeting RET in medullary thyroid cancer
Abstract:
Medullary thyroid cancer (MTC) is a rare cancer, accounting for 2-3% of all thyroid cancers. Point mutations in the RET proto-oncogene can be detected in 25-65% of MTC. These mutations commonly occur in the cysteine-rich or tyrosine kinase domains, leading to constitutively active tyrosine kinase activity in RET. In the last decade, significant advancements have been made in treating MTC with the advent of tyrosine kinase inhibitors, especially in RET-mutated MTC. Multikinase inhibitors such as vandetanib and cabozantinib were the first few effective inhibitors, which have been shown to slow disease progression in the treatment of advanced MTC. In more recent years, these have been followed by highly selective RET inhibitors selpercatinib and pralsetinib, which have made their way into the clinic, demonstrating high efficacy and a more favourable side-effect profile due to their reduction in off-target effects. In spite of these successes, there remains a continued need to develop strategies to overcome treatment resistance.
Insights
Medullary thyroid cancer (MTC) treatment has advanced with tyrosine kinase inhibitors targeting RET mutations. Newer, selective RET inhibitors offer improved efficacy and safety, though overcoming resistance remains crucial.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Medullary thyroid cancer (MTC) is a rare endocrine malignancy.
- RET proto-oncogene mutations are found in 25-65% of MTC cases, leading to aberrant kinase activity.
- Targeted therapies have revolutionized MTC treatment, particularly for RET-mutated tumors.
Purpose of the Study:
- To review the advancements in MTC treatment.
- To highlight the role of tyrosine kinase inhibitors in managing MTC.
- To discuss the evolution from multikinase inhibitors to selective RET inhibitors.
Main Methods:
- Review of clinical studies and literature on MTC therapeutics.
- Analysis of the efficacy and side-effect profiles of various tyrosine kinase inhibitors.
- Examination of the mechanism of action for RET-targeted therapies.
Main Results:
- Multikinase inhibitors (vandetanib, cabozantinib) demonstrated efficacy in advanced MTC.
- Selective RET inhibitors (selpercatinib, pralsetinib) show high efficacy with improved safety profiles.
- These newer agents reduce off-target effects, enhancing patient outcomes.
Conclusions:
- Tyrosine kinase inhibitors, especially selective RET inhibitors, represent significant progress in MTC therapy.
- Current treatments have improved disease control and patient well-being.
- Further research is needed to address and overcome treatment resistance in MTC.
